UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Idiopathic splanchnic vein thrombosis: is it really idiopathic?

Haematologica (Roma), 2023-05, Vol.108 (5), p.1208-1209

Barosi, Giovanni

2023

Volltextzugriff (PDF)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis

Haematologica (Roma), 2024-07

2024

Volltextzugriff (PDF)

Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?

Leukemia, 2019-03, Vol.33 (3), p.588-596

2019

Volltextzugriff (PDF)

Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”

Leukemia, 2019-05, Vol.33 (5), p.1301-1302

2019

Volltextzugriff (PDF)

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

Bone marrow transplantation (Basingstoke), 2020-06, Vol.55 (6), p.1093-1102

2020

Volltextzugriff (PDF)

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Volltextzugriff (PDF)

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter

Best practice & research. Clinical haematology, 2014-06, Vol.27 (2), p.129-140

Barosi, Giovanni, MD

2014

Volltextzugriff (PDF)

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis

Blood advances, 2019-06, Vol.3 (11), p.1729-1737

2019

Volltextzugriff (PDF)

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Blood, 2014-08, Vol.124 (7), p.1062-1069

2014

Volltextzugriff (PDF)

Spleen in myeloproliferative neoplasms

HemaSphere, 2018-06, Vol.2 (S2), p.173-174

Barosi, Giovanni

2018

Volltextzugriff (PDF)

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Blood, 2013-08, Vol.122 (8), p.1395-1398

2013

Volltextzugriff (PDF)

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Blood, 2009-03, Vol.113 (13), p.2895-2901

2009

Volltextzugriff (PDF)

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Blood, 2013-06, Vol.121 (23), p.4778-4781

2013

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

Haematologica (Roma), 2022-11, Vol.107 (11), p.2536-2547

2022

Volltextzugriff (PDF)

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Blood, 2011-07, Vol.118 (2), p.401-408

2011

Volltextzugriff (PDF)

Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines

Journal of clinical oncology, 1999-09, Vol.17 (9), p.2954-2970

BAROSI, G

1999

Volltextzugriff (PDF)

Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis

Leukemia, 2021-02, Vol.35 (2), p.468-475

2021

Volltextzugriff (PDF)

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Blood, 2017-10, Vol.130 (15), p.1768-1771

2017

Volltextzugriff (PDF)

EZH2 mutational status predicts poor survival in myelofibrosis

Blood, 2011-11, Vol.118 (19), p.5227-5234

2011

Volltextzugriff (PDF)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

Journal of hematology and oncology, 2019-12, Vol.12 (1), p.131-131, Article 131

2019

Volltextzugriff (PDF)

Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2007-02, Vol.25 (6), p.625-633

2007

Volltextzugriff (PDF)

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies

Clinical transplantation, 2019-10, Vol.33 (10), p.e13666-n/a

2019

Volltextzugriff (PDF)

1 – 25 von 425

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(401)
Mit Volltextzugriff
(381)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(235)
Humans
(233)
Life Sciences & Biomedicine
(227)
Hematology
(180)
Female
(110)
Male
(108)
Biological And Medical Sciences
(105)
Medical Sciences
(104)
Middle Aged
(98)
Adult
(92)
Hematologic And Hematopoietic Diseases
(80)
Aged
(79)
Oncology
(72)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(63)
Myelofibrosis
(50)
Mutation
(48)
Primary Myelofibrosis - Genetics
(43)
Primary Myelofibrosis - Pathology
(41)
Janus Kinase 2 - Genetics
(36)
Aged, 80 And Over
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Idiopathic splanchnic vein thrombosis: is it really idiopathic?

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis

Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?

Response to the Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Spleen in myeloproliferative neoplasms

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines

Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

EZH2 mutational status predicts poor survival in myelofibrosis

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies

Suchergebnisse filtern